Original articleNo evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis
Key words
Abbreviations used
Cited by (0)
Funding sources: The APPLES study (A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis) was initiated by Fujisawa and later sponsored by Astellas Pharma and LEO Pharma. LEO Pharma Inc, provided medical writing assistance for this publication.
Conflicts of interest: Dr Paller is an investigator for AbbVie, Anaptysbio, Celgene, Eli Lilly, Galderma, Incyte, LEO Pharma Inc, Janssen, Novartis, and Sanofi-Regeneron, and is a consultant with honorarium for AbbVie, Amgen, Asana, Celgene, Dermavant, Dermira, Galderma, Eli Lilly, Forte, LEO Pharma Inc, Menlo, Novartis, Pfizer, Regeneron, and Sanofi-Genzyme. Dr Fölster-Holst is a consultant, speaker, and clinical researcher for Almirall Hermal, Beiersdorf AG, Johnson & Johnson, LEO Pharma Inc, Neubourg GmbH, Novartis, Pierre Fabre, Pfizer, Procter & Gamble, Regeneron Pharmaceuticals, and Sanofi-Aventis. Dr Margolis is a consultant on atopic dermatitis for Pfizer, LEO Pharma Inc, and Sunovion, an advisor for the National Eczema Association, and receives research support from Valeant. Drs Chen, Diepgen, Elmets, and Pollock have no conflicts of interest to declare.
Parts of this study were presented as an abstract at the 28th European Academy of Dermatology and Venereology (EADV) Congress, Madrid Spain, October 9-13, 2019.
IRB approval status: An Institutional Review Board or Independent Ethics Committee for each participating site approved the study protocol.
This work is dedicated to the memory of Thomas L. Diepgen.